ALLHAT trial: Which BP drugs are best?

   Building new bone: PTH for osteoporosis

   Microalbuminuria: A new coronary risk factor?

   Bone density: Behind the numbers

   Practical tips for warfarin dosing

   Advances in heart failure: Drugs to devices

   Challenges and choices in chronic pain

   Prostate supplements: Promise or hype?

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Education Home | CCF Home | CCJM Home

The Cleveland Clinic Foundation
Cleveland Clinic Journal of Medicine
9500 Euclid Avenue, NA32
Cleveland, Ohio 44195

216.444.2661, FAX 216.444.9385
  ccjm@ccf.org

 

 

Cyber-CME and the Journal’s computer-literate readers
Congratulations to you, our readers, on your adaptability and computer literacy.
J.D. CLOUGH

 

Relieving migraine pain: Sorting through the options
Even with effective treatments, including new drugs in convenient dosage forms, the key is still a good working patient-physician relationship.
L.K. MANNIX

Patient Information     Migraine treatments--what you can expect
 

Polycystic ovary syndrome: Pathogenesis and treatment over the short and long term
PCOS can lead to serious sequelae such as endometrial or ovarian cancer, diabetes mellitus, and coronary artery disease.
T.L. MARX and A.E. MEHTA

 
  Brief answers to specific clinical questions
  Should everyone with a recent myocardia infarction receive a beta-blocker and an ACE inhibitor?
Yes, except for those with the standard contraindications to these drugs.
J.C. HOSTETTER and S. GHAFFARI
 

New guidelines: What to do about an unexpected positive tuberculin skin test
With tuberculosis declining in prevalence, the focus is shifting to testing only persons at increased risk.
C. CURLEY

Patient Information If your tuberculosis skin test is positive
 

Thyrotoxicosis and the cardiovascular system: Subtle but serious effects
One should suspect thyrotoxicosis in patients with palpitations, tachycardia, exercise intolerance, or dyspnea on exertion.
M. ROFFI, F. CATTANEO, and E.J. TOPOL

Brief answers to specific clinical questions
  Alosetron (Lotronex) is back: Should I use it to treat my patients with irritable bowel syndrome?
The FDA recently approved the remarketing of alosetron, but with strict limitations.
B. SHEN and E.E. SOFFER
 

A 62-year-old man with sudden onset of orthopnea and left shoulder weakness and pain
What is the cause of this patient’s symptoms? A self-test.
W.C. COOK and J. CHAPMAN

  

CME Self-test